Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  erlotinib hydrochloride
Find trials that include:  Any drugs shown
Results 1-25 of 33 for your search:
Start Over
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400, NCI-2014-00627, S1400A, S1400B, S1400C, S1400D, S1400E, S1400I, NCT02154490
Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A081105, NCI-2014-01508, CALGB A081105, NCT02193282
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 15540, NCI-2016-00365, 2014-004824-22, I4T-MC-JVCY, NCT02411448
Rilotumumab and Erlotinib Hydrochloride in Treating Patients With Recurrent or Progressive Advanced Non-Small Cell Lung Cancer Previously Treated With Chemotherapy
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 10-058, NCI-2011-02501, NCT01233687
FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0432, NCI-2011-03444, NCT01455389
Alisertib and Erlotinib Hydrochloride in Treating Patients with Recurrent Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TH-036, NCI-2011-03306, FER-TH-036, X14004, NCT01471964
Pacritinib and Erlotinib Hydrochloride in Treating Patients with Metastatic or Locally Advanced Non-small Cell Lung Cancer after EGFR TKI Treatment
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201503052, NCI-2015-00399, J20001, NCT02342353
A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BGBC004, NCI-2015-00730, NCT02424617
Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients with Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9878, NCI-2015-01411, PHI-80, NCT02535338
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-370, NCI-2016-00707, NCT02574078
Trametinib and Erlotinib Hydrochloride in Treating Patients with Stage IV or Recurrent Lung Cancer with EGFR Activating Mutation
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: 15-098, NCI-2017-00542, NCT03076164
Bevacizumab and Erlotinib Hydrochloride in Treating Patients with Hereditary Leiomyomatosis and Advanced Kidney Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-C-0114, NCI-2013-01459, 100114, P10628, NCT01130519
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients with Stage III Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RTOG-1306, NCI-2013-00737, NCT01822496
Erlotinib Hydrochloride before Surgery in Treating Patients with Stage III Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 2013-233, NCI-2013-02219, 2013-233-004, NCT01857271
Cisplatin or Carboplatin and Docetaxel with or without Erlotinib Hydrochloride in Treating Patients with Stage III-IVB Oral Cavity Cancer That Can Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0179, NCI-2014-01390, NCT01927744
Erlotinib Hydrochloride in Treating Patients with Bladder Cancer Undergoing Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: CO12336, NCI-2014-01320, HHSN261201200033I, N01-CN-2012-00033, UWI2013-01-02, NCT02169284
Erlotinib Hydrochloride and Temozolomide in Treating Younger Patients with Relapsed, Recurrent, or Refractory Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: 201604002, NCI-2016-00549, NCT02689336
Rapid Blood Test in Detecting EGFR Mutation for Early Initiation of Erlotinib Hydrochloride in Treating Patients with Advanced Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-093, NCI-2016-01371, NCT02770014
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients with Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
Status: Not yet active
Phase: Phase II
Type: Prevention
Age: 18 to 69
Trial IDs: MAY2016-07-01, NCI-2016-01674, N01-CN-2012-00042, NCT02961374
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00014171, NCI-2017-00510, NCT02693535
Maintenance Chemotherapy with or without Stereotactic Body Radiation Therapy in Treating Patients with Stage IV Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NRG-LU002, NCI-2016-00849, NCT03137771
Defined Green Tea Catechin Extract and Erlotinib Hydrochloride in Treating Patients with Premalignant Lesions or Previously Treated Early Stage Squamous Cell Cancer of the Head and Neck
Status: Active
Phase: Phase I
Type: Prevention
Age: 18 and over
Trial IDs: WCI1549-08, NCI-2011-03396, IRB00014010, WCI 1549, NCT01116336
Start Over